An interventional study of Intervention group in Diabetes Mellitus Type 2 and Hypertension, sponsored by VTT Technical Research Centre of Finland. Completed at 1 site in Finland. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by VTT Technical Research Centre of Finland · Not applicable, Interventional, and Treatment
Mobile Sipoo is a randomized controlled trial aiming to improve selfcare and outcomes of diabetes and hypertensive patients by introducing a remote patient monitoring system supported with automatic patient decision support. The feedback system is coupled with back-office health coaching.
Self-monitored data from blood pressure meters (SMBP), glucometers (SMBG), scales and pedometers are transferred by mobile phone terminals to a tethered personal health record (PHR) integrated with the provider EHR. The PHR application includes tools to display of self-monitoring data.
9,590 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.
This study's enrollment of 56 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →VTT Technical Research Centre of Finland is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Control group received usual care
Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
Device: Intervention group
Change in blood pressure
Time frame: 9 months
Change in Hba1c(for diabetes patients)
Time frame: 9 months
Achieving the desired target range
Target range for blood pressure is \<= 135/85 mmHg. Target range for glycohemoglobin is \<= 6.5%.
Time frame: 9 months
Adverse effects
hypotension, RR \< 120/80 mmHg
Time frame: 9 months
Hypoglycemia
p-glucose \< 3.5 mmol/l
Time frame: 9 months
Change in body weight
Time frame: 9 months
Change in BMI
Time frame: 9 months
Change in medication
Time frame: 9 months
Change in FÍNSIK scores
Time frame: 9 months
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VTT Technical Research Centre of Finland